EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Enhancing immune response in advanced HCC with PVTT: rivaroxaban as a core adjuvant in combined therapy

Ying Yan, Dan Zou, Yifan Li, Huanhuan Ma, Hao Chen

Journal for ImmunoTherapy of Cancer · 2026-04 · 14 (4) · e014060

DOI: 10.1136/jitc-2025-014060 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 27.04.2026. Verfasst von Ying Yan und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Cancer Center of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Rivaroxaban, Portal Vein. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Key Talents Project of Gansu Province, Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the establishment of combined local and systemic therapy as the standard approach for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT), its efficacy remains constrained by two primary challenges: the immunosuppressive tumor microenvironment (TME) and treatment resistance. Recent research shows that factor Xa (FXa) boosts programmed death-ligand 1 (PD-L1) expression in tumor cells via the proteinase-activated receptor-2 (PAR-2) and signal transducer and activator of transcription 2 (STAT2) pathways, aiding immune evasion. Rivaroxaban, an FXa inhibitor, prevents portal vein thrombosis and disrupts the FXa/PAR-2/PD-L1 axis, restoring T cell function. Based on this mechanism, we propose that incorporating rivaroxaban as a core adjuvant into a long-term, ‘local-targeted-immune’ multimodal strategy can spatiotemporally reprogram the TME in advanced HCC with PVTT. This approach has the potential to effectively overcome treatment resistance and achieve sustained disease control. The hypothesis is readily testable in clinical trials, and if substantiated, it could establish a new treatment paradigm aimed at improving the prognosis for this high-risk patient population. Furthermore, it would provide a robust theoretical rationale and practical guidance for advancing the treatment of advanced HCC with PVTT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsRivaroxabanPortal VeinVenous ThrombosisHumansTumor MicroenvironmentAnimalsImmunotherapyCombined Modality Therapy

Stichwörter der Autor:innen

Hepatocellular CarcinomaImmunotherapyTumor microenvironment - TME

Substanzen

Rivaroxaban

Autor:innen und Institutionen

  • The Cancer Center of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China.
  • Department of Surgical Oncology, Lanzhou University Second Clinical Medical School, Lanzhou, Gansu, China.
  • The Cancer Center of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China ery_chenh@lzu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Key Talents Project of Gansu Province
  • Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital
  • Major scientific research project for scientific and technological innovation in the health industry of Gansu Province
  • General Project of Gansu Province Joint Research Fund
  • Science and Technology Project of Chengguan District of Lanzhou City
  • Key Project of Science and Technology in Gansu province
  • Medical Research Innovation Ability Improvement Project of Lanzhou University

Zitieren

APA

Yan, Y., Zou, D., Li, Y., Ma, H., & Chen, H. (2026). Enhancing immune response in advanced HCC with PVTT: rivaroxaban as a core adjuvant in combined therapy. Journal for ImmunoTherapy of Cancer, 14(4), e014060. https://doi.org/10.1136/jitc-2025-014060

Vancouver

Yan Y, Zou D, Li Y, Ma H, Chen H. Enhancing immune response in advanced HCC with PVTT: rivaroxaban as a core adjuvant in combined therapy. Journal for ImmunoTherapy of Cancer. 2026;14(4):e014060. doi:10.1136/jitc-2025-014060

BibTeX
@article{Yan2026,
  author = {Yan, Ying and Zou, Dan and Li, Yifan and Ma, Huanhuan and Chen, Hao},
  title = {Enhancing immune response in advanced HCC with PVTT: rivaroxaban as a core adjuvant in combined therapy},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {4},
  pages = {e014060},
  doi = {10.1136/jitc-2025-014060}
}
Kostenlos starten →